SSRIs Do Not Worsen Parkinson's Disease: Evidence from an Open-Label, Prospective Study

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Clinical neuropharmacology

• Publication date

  2001-07-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/00002826-200107000-00005PMID 11479393
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Changes in rat dopamine- and serotonin function in vivo after prolonged administration of the specific 5-HT uptake inhibitor, citalopram

  2004cited by this paper
• Antidepressants in long‐term therapy: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors

  2000cited by this paper
• Paroxetine in Parkinson’s disease: Effects on motor and depressive symptoms

  2000cited by this paper
• Tolerability of paroxetine in Parkinson's disease: A prospective study

  2000cited by this paper
• Stimulus‐sensitive spinal segmental myoclonus improved with injections of botulinum toxin type A

  1999cited by this paper
• Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series

  1999cited by this paper
• SSRIs and movement disorders.

  1999cited by this paper
• The functional sensitisation of sigma receptors following chronic selective serotonin reuptake inhibitor treatment.

  1998cited by this paper
• Autonomic Neuropathy: Diagnosis and Impact on Health in Adolescents with Diabetes

  1998cited by this paper
• Managing the neuropsychiatric symptoms of Parkinson's disease

  1998cited by this paper
• Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease

  1997cited by this paper
• Sertraline for the treatment of depression in parkinson's disease

  1997cited by this paper
• The occurrence of depression in Parkinson's disease. A community-based study.

  1996cited by this paper
• SSRIs and movement disorders: is serotonin the culprit?

  1996cited by this paper
• Fluoxetine in Parkinson's disease

  1996cited by this paper
• Movement disorders associated with the serotonin selective reuptake inhibitors.

  1996cited by this paper
• Fluoxetine and extrapyramidal side effects.

  1995cited by this paper
• Brain damage and tardive dyskinesia

  1995cited by this paper
• Does fluoxetine aggravate Parkinson's disease? A pilot prospective study

  1995cited by this paper
• Fluoxetine and Selegiline – Lack of Significant Interaction

  1994cited by this paper
• Parkinsonism exacerbated by paroxetine

  1994cited by this paper
• Worsening of parkinsonism with fluvoxamine—two cases

  1994cited by this paper
• Recent pharmacologic advances in antidepressant therapy for the elderly.

  1993cited by this paper
• Serotonin-facilitated dopamine release in vivo: pharmacological characterization.

  1993cited by this paper
• Increase of Parkinson disability after fluoxetine medication.

  1993cited by this paper
• Neurobiological mechanisms involved in antidepressant therapies.

  1993cited by this paper
• Does fluoxetine exacerbate Parkinson's disease?

  1992influential reference
• Serotonergic dysfunction in depression associated with Parkinson's disease

  1992cited by this paper
• Depression and Parkinson's disease: a review.

  1992cited by this paper
• A case of Parkinson's disease exacerbated by fluoxetine

  1992cited by this paper
• The serotonin syndrome.

  1991cited by this paper
• The Neuropathologic Basis of Different Clinical Subgroups of Parkinson's Disease

  1991cited by this paper
• Depression in the patient with Parkinson's disease.

  1990cited by this paper
• Fourier's view on homosexuality.

  1989cited by this paper
• Fluoxetine and extrapyramidal side effects.

  1989cited by this paper
• The effects of antidepressants and electroconvulsive shocks on the functioning of the mesolimbic dopaminergic system: a behavioral study.

  1987cited by this paper
• Clinical and biochemical features of depression in Parkinson's disease.

  1986cited by this paper
• Parkinson's disease: decreased density of 3H-imipramine and 3H- paroxetine binding sites in putamen

  1986cited by this paper
• Altered serotonin metabolism in depressed patients with Parkinson's disease

  1984cited by this paper
• Biochemical substrates of mental disturbances in Parkinson's disease.

  1984cited by this paper
• Brain neurotransmitter changes in Parkinson's disease

  1981cited by this paper
• Anti‐depressive treatment in Parkinson's disease A CONTROLLED TRIAL OF THE EFFECT OF NORTRIPTYLINE IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH L‐DOPA

  1980cited by this paper
• Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant

  1979cited by this paper
• Desipramine in treatment of Parkinson's disease. A placebo-controlled study.

  1969cited by this paper
• DESIPRAMINE IN TREATMENT OF PARKINSON'S DISEASE

  1969cited by this paper
• Imipramine in Treatment of Parkinsonism: a Double-blind Placebo Study

  1965cited by this paper
• An inventory for measuring depression.

  1961cited by this paper
• Imipramine Hydrochloride (Tofranil) in Parkinsonism: A Preliminary Report

  1961cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• Repurposing Sigma-1 Receptor-Targeting Drugs for Therapeutic Advances in Neurodegenerative Disorders

  2025cites this paper
• Treatment options for depression in Parkinson's disease: a mini-review.

  2025cites this paper
• The effect of serotonin reuptake and serotonin-noradrenaline reuptake inhibitors on motor symptoms in Parkinson's disease: A PPMI-based matched-subject study

  2024cites this paper
• Serotonin as a biomarker of toxin-induced Parkinsonism

  2024cites this paper
• Spectrum of Non-Motor Symptoms in Parkinson’s Disease — a Review

  2024cites this paper
• Vortioxetine Improved Depressive State In Parkinson’s Disease

  2021cites this paper
• Desarrollo de herramienta informática para el fácil acceso a tratamientos farmacológicos en neurología

  2020cites this paper
• Pharmacological management of Parkinson’s disease in older people

  2020cites this paper
• Spezielle Aspekte bezogen auf Organsysteme nach geriatrisch-klinischer Bedeutung

  2019cites this paper
• Treatment of psychiatric disturbances in hypokinetic movement disorders

  2019cites this paper
• Evidence of Repurposing Drugs and Identifying Contraindications from Real World Study in Parkinson's Disease.

  2019cites this paper
• A review of citalopram dose restrictions in the treatment of neuropsychiatric disorders in older adults

  2019cites this paper
• Antidepressants in Parkinson's disease. Recommendations by the movement disorder study group of the Neurological Association of Madrid

  2018influential citation
• Employment issues and vocational rehabilitation considerations for people with Parkinson’s disease: A review of the literature and a call to action

  2018influential citation
• USING THE INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY, AND HEALTH TO PREDICT PARTICIPATION IN ADULTS WITH PARKINSON’S DISEASE: THE ROLE OF POSITIVE PSYCHOLOGICAL CAPITAL

  2018cites this paper
• Prevalence of depression and receipt of antidepressant pharmacotherapy among patients with Parkinson’s disease: a national assessment of US office-based physician visits

  2017cites this paper
• Antidepressants in Parkinson's disease. Recommendations by the movement disorder study group of the Neurological Association of Madrid.

  2016cites this paper
• AND Key cogs in the management of Parkinson ’ s disease

  2016cites this paper
• Antidepresivos en la enfermedad de Parkinson. Recomendaciones del grupo de trastornos del movimiento de la Asociación Madrileña de Neurología

  2016cites this paper
• Depression in Parkinson's disease: the effectiveness and risk of pharmacotherapy. Clinical review

  2015cites this paper
• Antidepressive treatments for Parkinson's disease: A systematic review and meta-analysis.

  2015cites this paper
• A Case of SSRI Induced Irreversible Parkinsonism.

  2015cites this paper
• Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.

  2015cites this paper
• Monoamine Reuptake Inhibitors in Parkinson's Disease

  2015cites this paper
• ÖSSZEFOGLALÓ KÖZLEMÉNY DEPRESSION IN PARKINSON ’ S DISEASE

  2014cites this paper
• Anxiety in Parkinson’s disease: identification and management

  2014cites this paper
• A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs by D. G. Cunningham Owens

  2014cites this paper
• Depression in Parkinson's disease.

  2014cites this paper
• The pharmacologic management of depression in Parkinson's disease.

  2013cites this paper
• Psychiatric Care in Parkinson’s Disease

  2013cites this paper
• Management of anxiety and depression

  2013cites this paper
• Parkinson’s Disease – the Debate on the Clinical Phenomenology, Aetiology, Pathology and Pathogenesis

  2013cites this paper
• Depression in Parkinson's disease: An update

  2013cites this paper
• Depression in Parkinson's Disease: Identification and Management

  2013cites this paper
• Fluoxetine does not impair motor function in patients with Parkinson's disease: correlation between mood and motor functions with plasma concentrations of fluoxetine/norfluoxetine.

  2012cites this paper
• Citalopram versus other anti-depressive agents for depression.

  2012cites this paper
• A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease

  2012cites this paper
• Overview of the Medical Treatment of the Non‐Motor and Non‐Dopaminergic Features of Parkinson's Disease

  2011cites this paper
• Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation.

  2011cites this paper
• Pathological considerations in the treatment of Parkinson's disease: more than just a wiring diagram.

  2011cites this paper
• Serotonin-dependent depression in Parkinson's disease: a role for the subthalamic nucleus?

  2011cites this paper
• Nonmotor Symptoms in Parkinson's Disease

  2011cites this paper
• Extrapyramidal Symptoms Associated with Antidepressants—A Review of the Literature and An Analysis of Spontaneous Reports

  2010cites this paper
• Chronic treatment with fluoxetine decreases cerebral metabolic responses to the 5-HT1A agonist 8-hydroxy-2(di-N-propylamino)tetralin and increases those to the 5-HT2A/2C agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and to the dopaminergic agonist apomorphine.

  2010cites this paper
• Destruction of Dopaminergic Neurons in the Midbrain by 6-Hydroxydopamine Decreases Hippocampal Cell Proliferation in Rats: Reversal by Fluoxetine

  2010cites this paper
• Affect in Parkinson's disease: validation of the two-factor approach.

  2010cites this paper
• Fluoxetine as disease modifying treatment in multiple sclerosis: rationale, evaluation of the use of MRI to monitor treatment, and preliminary findings

  2009cites this paper
• Non-motor symptoms in Parkinson’s disease

  2009cites this paper
• Medical treatment of Parkinson disease.

  2009cites this paper
• Selective Serotonin Reuptake Inhibitors Effect on Motor Function in Subjects with Parkinson’s Disease and Depression

  2009cites this paper
• Dopamine receptor agonists and depression in Parkinson's disease.

  2009cites this paper
• Avaliação do tratamento de depressão em pacientes com doença de Parkinson através de ressonância magnética funcional

  2009cites this paper
• Therapie geriatrischer Patienten mit Morbus Parkinson

  2009cites this paper
• Medical Comorbidities in Late-Life Depression

  2008cites this paper
• Therapeutic Potential of Fluoxetine in Neurological Disorders

  2008cites this paper
• Diagnosis and treatment of depression comorbid with neurologic disorders.

  2008cites this paper
• Optimizing therapeutic effects in patients with comorbidities: drug-resistant tremor, autonomic dysfunction, psychiatric disorders, and cognitive impairment.

  2008cites this paper
• Sertraline in the treatment of depressive disorders in patients with Parkinson’s disease

  2008cites this paper
• Tolerability of Selective Serotonin Reuptake Inhibitors

  2008cites this paper
• Parkinson disease: Not just a movement disorder

  2008cites this paper
• Depression rating scales in Parkinson's disease: Critique and recommendations

  2007cites this paper
• Management of the behavioral aspects of Parkinson’s disease

  2007cites this paper
• Bright light therapy in Parkinson's disease: A pilot study

  2007cites this paper
• Drug-induced parkinsonism.

  2007cites this paper
• Disorders of mood and affect in Parkinson's disease.

  2007cites this paper
• Alien limb following posterior cerebral artery stroke: Failure to recognize internally generated movements?

  2007cites this paper
• Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients

  2007cites this paper
• Neurobehavioral disorders in Parkinson's disease.

  2007cites this paper
• Demenz und Depression bei Patienten mit idiopathischem Parkinson-Syndrom

  2007cites this paper
• The Effects of Acute Tryptophan Depletion on Movement, Mood, and Cognition in Patients with Parkinson’s Disease and Healthy Older Persons

  2007influential citation
• Antidepressants for depressed elderly.

  2006cites this paper
• Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode.

  2006cites this paper
• Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study.

  2006cites this paper
• Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission: implications in physiological functions and in pathology.

  2006cites this paper
• Treatment of depression in Parkinson’s disease

  2006cites this paper
• The effect of depression on motor function and disease severity of Parkinson's disease.

  2006cites this paper
• Cognitive, affective, and psychiatric features of Parkinson's disease.

  2006cites this paper
• Cognitive and psychiatric aspects of Parkinson's disease: treatment recommendations

  2006cites this paper
• Non-Motor Aspects of Parkinson's Disease

  2006cites this paper
• Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease

  2006cites this paper
• Initial treatment of parkinson’s disease

  2006cites this paper
• A matter of motion or an emotional matter? Management of depression in Parkinson’s disease

  2005cites this paper
• Current approaches to management of depression in Parkinson's Disease.

  2005cites this paper
• Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression

  2005cites this paper
• Treatment of depression in the medically ill.

  2005cites this paper
• Monoaminergic‐based Pharmacotherapy for Depression

  2005cites this paper
• Prevalence and treatment of depression in Parkinson's disease.

  2005cites this paper
• Treatment of behavioural symptoms and dementia in Parkinson's disease

  2005cites this paper
• Affektive Symptome beim Morbus Parkinson und atypischen Parkinson-Syndromen

  2005cites this paper
• The association between spirituality and depression in Parkinson's disease

  2005cites this paper
• Antidepressant studies in Parkinson's disease: A review and meta‐analysis

  2005cites this paper
• Treatment of Depression in the Medically Ill

  2005cites this paper
• Antidepressant medication use and restless legs syndrome in patients presenting with insomnia.

  2005cites this paper
• Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice.

  2005cites this paper
• Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition.

  2004cites this paper
• Psychiatric aspects of Parkinson’s disease

  2004cites this paper
• Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson’s disease

  2004cites this paper
• The neuropsychiatry of Parkinson's disease and related disorders.

  2004cites this paper
• Anxiety, depression, and psychosis in Parkinson's disease: unmet needs and treatment challenges.

  2004cites this paper
• Treatment of depression in Parkinson's disease.

  2004cites this paper